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Isolated limb perfusion (ILP) is considered the method of choice
for the treatment of patients with multiple in-transit melanoma
metastases confined to an extremity (Eggermont, 1996).
Melphalan has been the standard drug for this regional treatment
because of low regional toxicity (Thompson and Gianoutsos,
1992). ILPs with melphalan or other cytostatic drugs has also been
used in the treatment of patients with extremity soft tissue
sarcomas, although with little success (Kremetz et al, 1977; Klaase
et al, 1989). Therefore, Liénard et al (1992) pioneered the applica-
tion of high-dose tumour necrosis factor (TNF)-a and interferon
gamma (IFN-g) with melphalan, which was reported to result in
very high complete response rates in melanoma patients. The
impact of using TNF in this setting has been greatest, however, in
the treatment of patients with irresectable extremity soft tissue
sarcomas, as response rates and limb salvage rates of more than
80% have been reported in large series of patients destined for
amputation of the limb (Eggermont et al, 1996a, 1996b). The
selective destruction of tumour vasculature, resulting in haemor-
rhagic necrosis of the tumour, has been shown in angiographic and
histopathological studies (Renard et al, 1994; Eggermont et al,
1996a).
Yet many questions regarding mechanisms or conditional
requirements by which ILP with TNF and melphalan are mediated,
are not solved. Therefore, a tumour model with a highly aggres-
sive non-immunogenic soft tissue sarcoma in BN rats was
developed in our laboratory to address these questions (Manusama
et al, 1996). Response after ILP with melphalan and TNF in this
model correspond well to what is observed in sarcoma patients in
terms of synergy between TNF and melphalan, response rate, and
histopathological observations (Manusama et al, 1996; Nooijen
et al, 1996a). This rat model could therefore serve as a credible
model to study mechanisms and determine ways to optimize ILP
efficacy for the clinical setting. Here we address requirements for
an effective ILP setting, such as temperature of the perfusate and
limb, duration of the perfusion, oxygenation of the perfusate and
concentration of TNF.
MATERIAL AND METHODS
Animals
Male, inbred BN rats, weighing 250–300 g, obtained from Harlan-
CPB (Austerlitz, The Netherlands) were used for isolated limb
perfusions. Rats were fed a standard laboratory diet ad libitum
(Hope Farms Woerden, The Netherlands) and were housed under
standard conditions. The experimental protocols adhered to the
rules outlined in the Dutch Animal Experimentation Act (1977)
and the published ‘Guidelines on the Protection of Experimental
Animals’ by the Council of the E.C. (1986). The protocol was
approved by the committee on Animal Research of the Erasmus
University Rotterdam, The Netherlands.
Melphalan
Melphalan (Alkeran, 50 mg per vial, Wellcome, Beckenham, UK)
was diluted in 10 ml solvent. Further dilutions were made in 0.9%
sodium chloride to give a concentration of 1 mg ml–1. A volume of
40 ml (= 40 mg) was added to the perfusion circuit.
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Summary An isolated limb perfusion (ILP) model using soft tissue sarcoma-bearing rats was used to study prerequisites for an effective ILP,
such as oxygenation of the perfusate, temperature of the limb, duration of the perfusion and concentration of tumour necrosis factor (TNF).
Combination of 50 mg TNF and 40 mg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%. In
comparison to oxygenated ILP, hypoxia was shown to enhance anti-tumour activity of melphalan alone and TNF alone but not of their
combined use. Shorter perfusion times decreased anti-tumour responses. At a temperature of 24–26°C, anti-tumour effects were lost,
whereas temperatures of 38–39°C or 42–43°C resulted in higher response rates. However, at 42–43°C, local toxicity impaired limb function
dramatically. Synergy between TNF and melphalan was lost at a dose of TNF below 10 mg in 5 ml perfusate. We conclude that the
combination of TNF and melphalan has strong synergistic anti-tumour effects in our model, just as in the clinical setting. Hypoxia enhanced
activity of melphalan and TNF alone but not the efficacy of their combined use. For an optimal ILP, minimal perfusion time of 30 min and
minimal temperature of 38°C was mandatory. Moreover, the dose of TNF could be lowered to 10 mg per 5 ml perfusate, which might allow the
use of TNF in less leakage-free or less inert perfusion settings.
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Recombinant human TNF (rHuTNF) was provided by Boehringer
(Ingelheim, Germany) having a specific activity of 5.8 ´ 107 U
mg–1 as determined in the murine L-M cell assay (Kramer and
Carver, 1986). Endotoxin levels were < 1.25 endotoxin units (EU)
per mg protein. TNF concentrations used were 2, 10 and 50 mg in
5 ml perfusate.
ILP model
The perfusion technique was performed as described previously
(Manusama et al, 1996). Briefly, small fragments (3–5 mm) of the
rapidly growing and metastasizing BN-175 soft tissue sarcoma
were implanted subcutaneously into the right hind limb. Perfusion
was performed at a tumour diameter of 13 mm ± 3 mm at least
7 days after implantation. Animals were anaesthetized with
Hypnorm (Janssen Pharmaceutica, Tilburg, The Netherlands) and
50 IU of heparin were injected intravenously to prevent coagula-
tion. To keep the rat’s hind limb at a constant temperature, a warm
water mattress was applied. Temperature was measured with a
temperature probe on the skin covering the tumour and was varied
between room temperature (24–26°C), ‘mild’ hyperthermia
(38–39°C) and ‘true’ hyperthermia (42–43°C). The femoral artery
and vein were cannulated with silastic tubing (0.012 inch inner
diameter (ID), 0.025 inch outer diameter (OD); 0.025 inch ID,
0.047 inch OD respectively; Dow Corning, Michigan, USA).
Collaterals were occluded by a groin tourniquet, and isolation time
started when the tourniquet was tightened. An oxygenation
reservoir and a roller pump were included into the circuit. The
perfusion solution was 5 ml Haemaccel (Behring Pharma,
Amsterdam, The Netherlands) and the haemoglobin (Hb) content
of the perfusate was 0.9 mmol-l–1. Melphalan and TNF were added
as boluses to the oxygenation reservoir. A roller pump (Watson
Marlow, Falmouth, UK; type 505 U) recirculated the perfusate at
a flow rate of 2.4 ml min. A washout with 5 ml oxygenated
Haemaccel was performed at the end of the perfusion. Subsequent
tumour growth after perfusion was daily recorded by caliper
measurement. Tumour volume was calculated as 0.4(A2B), where
A is the minimal tumour diameter and B the diameter perpen-
dicular to A.
Assessment of TNF concentrations in perfusate
During ILP samples for determination of TNF concentrations were
collected from the oxygen reservoir at 0.5, 5, 15 and 30 min.
Samples were centrifuged and an aliquot of the supernatant was
used for analysis. Enzyme-linked immunosorbent assay (ELISA)
for rHuTNF was performed as described by Engelberts et al
(1991). In short, a 96-well Immuno-Maxisorp plate was coated
with murine anti-human TNF monoclonal antibody (mAb) 61E71.
A standard titration curve was obtained by making serial dilutions
of a known sample of rHuTNF in normal rat serum. Standards and
samples were added to the wells and, after washing, the plates
were incubated with a polyclonal rabbit antihuman TNF anti-
serum, followed by addition of an enzyme-labelled antirabbit
reagent and enzyme reaction. The detection limit for human TNF
is 20 pg ml–1.
Assessment of melphalan concentrations in perfusate
During ILP, samples for determination of melphalan concentra-
tions were collected from the oxygen reservoir at 0.5, 5, 15 and
30 min. Melphalan was measured by gas chromatography–
mass spectrometry (GC-MS) (De Boeck et al, 1997). P-[Bis
(2-chloroethyl)amino]-phenylacetic acid methyl ester was used as
an internal standard. Samples were extracted over trifunctional
C18 silica columns. After elution with methanol and evaporation,
the compounds were derivatized with trifluoroacetic anhydride
and diazomethane in ether. The stable derivates were separated on
a methyl phenyl siloxane GC capillary column and measured
selectively by single ion monitoring GC-MS in the positive
EI mode.
Assessment of tumour response
The classification of tumour response was: progressive disease
(PD) = increase of tumour volume (> 25%) within 5 days; no
change (NC) = tumour volume equal to volume during perfusion
(in a range of –25% and +25%); partial remission (PR) = decrease
of tumour volume (–25 and –90%); complete remission (CR) =
tumour volume 0–10% of volume during perfusion or skin
necrosis.
Assessment of limb function
Limb function was a ‘clinical’ observation in which the rat’s
ability to walk and stand on the perfused limb was scored 5 days
after ILP. On this scale a severe impaired function (grade 0) means
that the rat drags its hindlimb without any function; a slightly
impaired function (grade 1) means the rat does not use its hindlimb
in a usual matter, but stands on it when rising; an intact function of
the hindlimb (grade 2) means a normal walking pattern.
Statistical analysis
Mann–Whitney U-test was used to compare tumour volumes in
different animal groups and to compare different tumour responses
in different groups. Calculations were performed on a personal
computer using Graph PadPrism and SPSS for Windows 95.
RESULTS
Synergy between TNF and melphalan
In the present study comprising experiments in 167 rats, the
efficacy of ILP with TNF and melphalan as reported previously
was confirmed (Figure 1) (Manusama et al, 1996). Synergy was
demonstrated for the combination of 50 mg TNF and 40 mg
melphalan. At 5 days after ILP a significant difference was
observed in mean tumour volume as compared to sham perfusions
(P < 0.001), TNF perfusions alone (P < 0.001) and melphalan
perfusion alone (P < 0.001). No significant difference was found
between all other groups.
Oxygenation/hypoxia
Differences in tumour response in oxygenated versus hypoxic
perfusions are summarized in Table 1. Sham oxygenated and
hypoxic perfusions resulted in progressive disease in all animals.
In oxygenated TNF perfusions, progressive disease occurred in all
animals as well; however, significant anti-tumour effect was
observed in hypoxic perfusions with TNF in comparison with
TNF alone (P < 0.001). Hypoxia also significantly increased the
162 JHW de Wilt et al
British Journal of Cancer (1999) 80(1/2), 161–166 © Cancer Research Campaign 1999anti-tumour response after ILP with melphalan (P = 0.03) as
compared to oxygenated perfusions with melphalan alone.
Oxygenated ILP with melphalan and TNF resulted in an overall
response rate of 71%. No further improvement of this effect was
demonstrated in hypoxic perfusions with the combination of
melphalan and TNF. In all hypoxic perfusions, no additional limb
toxicity was observed as compared with oxygenated perfusions
(data not shown).
TNF and melphalan concentrations during perfusion
Pharmacokinetic studies of TNF and melphalan in the perfusate
were performed, which shows a minimal decrease during perfu-
sion of TNF concentrations, indicating a leakage-free perfusion
system and a continuous exposure of the vasculature of high levels
of TNF (Figure 2). Melphalan concentrations, on the other hand,
decreased dramatically in the first minutes of ILP, indicating rapid
uptake by the tissues of the limb (Figure 2).
Hyperthermia
Standard perfusions with TNF and melphalan were performed
with ‘mild’ hyperthermia (38–39°C). At day 5 after perfusion, rats
perfused at room temperature (24–26°C) show almost no anti-
tumour effects versus the high response rates seen with ‘mild’ and
‘true’ hyperthermic conditions (both P < 0.001). Quality of
response (percentage of CR) was not further increased by ‘true’
hyperthermia in comparison with ‘mild’ hyperthermia, whereas
toxicity to the normal tissues was significantly enhanced leading to
increased grade 0 function of the limb (= severe impairment) in
this group (Table 2).
Perfusion time
A gradual, and almost complete, loss of efficacy was observed
when perfusion time was reduced from 30 min to 10 min. Table 3
demonstrates the effect of different perfusion times on tumour
response of TNF and melphalan. Response rates decreased from
71% to 45% (P < 0.005). Moreover, complete responses decreased
from 17 out of 28 animals at 30 min to 0 out of 11 animals at
10 min.
Minimally required TNF dose
Standard perfusions were performed with 50 mg TNF in 5 ml
perfusate on rats that weighed approximately 250 g. A de-escala-
tion study demonstrated similar overall response rates of > 70% at
10 mg (= 40 mg kg–1) and 50 mg TNF (= 200 mg kg–1) (Table 4). A
small (but not significant) drop in complete responses was
observed at 10 mg TNF. At 2 mg TNF (= 8 mg kg–1) no synergy
TNF limb perfusion in a rat model 163
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Figure 1 Growth curves of BN-175 sarcoma after 50 mmg TNF (s; n = 11),
40 mg melphalan ( t n = 13), TNF plus melphalan (n; n = 28) and sham
isolated limb perfusion (•; n = 12). Mean (± s.e.m) of tumour volumes are
shown
Figure 2 Concentration (ng ml–1) of TNF (•; n = 5) and melphalan
(n ; n = 5) in the perfusate as a function of time in rats. During isolated limb
perfusion 50 mg TNF with 40 mg melphalan was added to 5 ml perfusate as
a bolus
Table 1 Tumour responses of BN-175 sarcoma after isolated limb perfusion with or without hypoxia
Sham TNF Melphala Melphalan Melphalan + TNF
Sham + hypoxia TNF + hypoxia Melphalan + hypoxia Melphalan + TNF + hypoxia
Tumour response (n = 12) (n = 10) (n = 11) (n = 11) (n = 13) (n = 10) (n = 28) ( n = 18)
Progressive disease 12 10 11 3 3 2 2
No change 2 10 7 6 3
Partial response 5 3 3 9
Complete response 1 17 4
Percentage responses 55 30 71 72
(partial and complete)
Perfusions were performed with 50 mg TNF and 40 mg melphalan under constant temperature (38–39°C) for 30 min.with melphalan was observed, this anti-tumour response differed
significantly with 10 mg (P = 0.01) and 50 mg (P < 0.001). No
complete remissions, and only one partial response, were
observed, which corresponds to what is usually observed after an
ILP with melphalan alone. These findings indicate that the dose of
TNF can be reduced five- to tenfold without effecting response
rates, which might facilitate the use of TNF in less leakage-free
settings or at sites more responsive to the toxic effect of TNF.
DISCUSSION
The non-immunogenic BN-175 soft tissue sarcoma model in BN
rats has previously been shown to be an adequate model to address
questions for the clinical situation as response patterns to TNF,
melphalan and their combination (Manusama et al, 1996).
Moreover, histopathologic observations (Nooijen et al, 1996a)
closely resemble observations in patients (Renard et al, 1994;
Nooijen et al, 1996b). TNF alone is not active (Posner et al, 1994)
and melphalan is only marginally active in soft tissue sarcoma
(Kremetz et al, 1977; Klaase et al, 1989), whereas the combination
results in very high response rates in this rat model just as in
melanoma patients (Liénard et al, 1992; Fraker et al, 1996) or soft
tissue sarcoma patients (Eggermont et al, 1996a; 1996b). Here we
report on 167 ILPs to determine ways to optimize ILP efficacy for
the clinical setting. Wu et al (1997) previously demonstrated that
high flow rate and protein-free perfusate may enhance the effec-
tiveness of ILP with melphalan alone in nude rats. The require-
ments for a successful ILP such as oxygenation of the perfusate,
temperature of the limb, duration of the perfusion and concentra-
tion of TNF are addressed in this study. Regarding the factors
studied here, results are in line with clinical observations, although
these elements have never been studied in a direct comparative
fashion in the clinic.
Hypoxia can increase the sensitivity of tumour cells to
chemotherapeutic agents since it can cause dividing cells to halt
their progression through the cell cycle, by allowing them to
progress to and then remain in a G1-like susceptible state (Vaupel
et al, 1989). Since Thompson et al (1994) published results of
hypoxic ILP, the question whether the much more expensive
oxygenated ILPs using a heart–lung machine are really necessary
for the treatment of patients with multiple melanoma metastases
remains unanswered. We observed that hypoxia enhanced the
effects of TNF alone. Similarly, hypoxia enhanced effects of
melphalan alone, in line with Skarsgards et al (1995) who reported
increased cytotoxicity of melphalan with hypoxia both in vitro and
in vivo. Part of the enhancement of the anti-tumour effects by
hypoxia could be mediated by the reperfusion injury associated
with hypoxic perfusions and absent during oxygenated perfusions.
This reperfusion injury apparently would have a preferential effect
on the tumour as no impairment of limb function, as a measure of
local toxicity, is observed in hypoxic perfusions. Hypoxia did not
further increase the efficacy of the combination of TNF and
melphalan. Presumably the potential enhancing effect was over-
shadowed by the synergism of the combination of TNF and
melphalan, which again seems to be the central and crucial
phenomenon. For the clinical situation it remains an interesting
question whether the use of the oxygenator can be abandoned
without causing an increase in regional toxicity as has been
observed in the hypoxic setting in our model.
The application of hyperthermia in ILP is advocated since it has
been shown that the in vivo drug uptake by in-transit metastases is
higher at 39.5°C than at 37°C (Omlor et al, 1992) and that hyper-
thermia enhance anti-tumour effects of melphalan dramatically in
vitro (Clark et al, 1994; Robins et al, 1995). Hyperthermia also
enhances anti-tumour effects of TNF, as was demonstrated in
different tumour models in vitro and in vivo (Niitsu et al, 1988;
Watanabe et al, 1988a; Klostergaard et al, 1992). We observed that
the results in our animal model run parallel to the observations in
the clinic. Only perfusions at ‘mild’ or ‘true’ hyperthermia
resulted in a synergistic anti-tumour response of TNF and
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Table 2 Tumour responses of BN-175 sarcoma after isolated limb perfusion
with different temperature conditions
Melphalan + TNF Melphalan + TNF Melphalan + TNF
24–26°C 38–39°C 42–43°C
Tumour response (n = 12) (n = 28) (n = 10)
Progressive disease 6 2
No change 6 6
Partial response 3 7
Complete response 17 3
Percentage responses 71 100
(partial and complete)
Severe impaired limb 0/12 (0%) 6/28 (21%) 8/10 (80%)
function (grade 0)
Perfusions were performed with 50 mg TNF and 40 mg melphalan with
oxygenation for 30 min.
Table 3 Tumour responses of BN-175 sarcoma after isolated limb perfusion
with variable perfusion times
Melphalan + TNF Melphalan + TNF Melphalan + TNF
10 min 20 min 30 min
Tumour response (n = 11) (n = 10) (n = 28)
Progressive disease 3 1 2
No change 3 3 6
Partial response 5 3 3
Complete response 3 17
Percentage responses 45 60 71
(partial and complete)
Perfusions were performed with 50 mg TNF and 40 mg melphalan under
constant temperature (38–39°C) and with oxygenation.
Table 4 Tumour responses of BN-175 sarcoma after isolated limb perfusion
with variable TNF concentrations
2 mg TNF + 10 mg TNF + 50 mg TNF +
40 mg melphalan 40 mg melphalan 40 mg melphalan
Tumour response (n = 10) (n = 10) (n = 28)
Progressive disease 3 1 2
No change 6 2 6
Partial response 1 3 3
Complete response 4 17
Responses (%) 10 70 71
(partial and complete)
Perfusions were performed under constant temperature (38–39°C), with
oxygenation and for 30 min. TNF and melphalan doses are total doses
added to 5 ml perfusate as a bolus.melphalan, whereas after ILP at 24–26°C all anti-tumour effects
were lost. Hyperthermia not only demonstrated to potentiate anti-
tumour responses in our animal model, but also increased regional
toxicity dramatically when temperatures were above 42°C, which
is in line with our clinical experience (Kroon et al, 1992).
There are no clinical or preclinical studies that compare
different perfusion times in ILP. Traditionally a perfusion time of
1 h has been adopted for ILPs in patients with melphalan based on
pharmacokinetic patterns that request a duration of at least 30 min.
The pharmacokinetic profile of melphalan in the perfusate in our
model showed a similar rapid decrease in melphalan concentra-
tions as was previously demonstrated by others (Benckhuijsen
et al, 1988; Scott et al, 1992). We therefore did not study perfu-
sions longer than 30 min and were more interested if identical
results could be obtained after shorter perfusions. It was shown
that 30 min is optimal and that lesser efficacy was observed after
ILPs of 20 or 10 min. This is probably due to the fact that exposure
times over 20 min are needed to get the vascular occlusive and
destructive effects of TNF, needed for adequate tumour responses.
TNF is the crucial element in the observed synergy with
melphalan. Low-dose TNF has a proliferative effect on angiogen-
esis, whereas higher doses can cause destruction of newly formed
blood vessels (Fajardo et al, 1992). This destruction of blood
vessels may lead to thrombocyte aggregation, erythrostasis and
haemorragic necrosis found in tumours after treatment with TNF
(Watanabe et al, 1988b; Renard et al, 1994, 1995; Nooijen et al,
1996b). In clinical ILP treatment schedules TNF is used in high
doses (4 mg for a lower extremity) to induce the above described
effects. This dose is 10- to 50-fold higher than the maximum toler-
ated dose after intravenous administration in cancer patients
(Asher et al, 1987). It was shown that increasing TNF administra-
tion did not result in higher response rates but induced regional
toxicity to the perfused limb (Fraker et al, 1996). It will obviously
add to the safety of the procedure if one can reduce the dose of
TNF, while retaining its anti-tumour effects. Pharmacokinetic
observations of TNF in the perfusate in this animal model are
similar to the clinical situation, in which TNF concentrations
remain stable during perfusions (Vrouenraets et al, 1997). Since
there is a plateau in TNF levels well above saturation and thus well
above threshold level, lower TNF concentrations seems to point to
a reasonable action. However, it is not easy to perform a dose de-
escalation study in the clinical setting because of the large number
of patients needed for such a study. The only publication from Hill
et al (1993), in which TNF was used in about five- to sixfold lower
concentrations, demonstrated similar high response rates for soft
tissue tumours. With a de-escalation study we demonstrated the
minimally required TNF dose in our rat model to obtain synergy
with melphalan to be 10 mg (= 40 mg kg–1).
Since rHuTNF in mice binds only to the p55 receptor and not to
the p75 receptor its activity and toxicity is 5–10 times less than
murine TNF (MuTNF) (Brouckaert et al, 1992). Also in rats,
rHuTNF is at least 5 times more toxic than MuTNF as we
established that an intravenous dose of 40 mg MuTNF is lethal in
rats (Scheringa et al, 1989), whereas doses of 200 mgr HuTNF are
not lethal (own observations). This phenomenon can be explained
if we assume that the same receptor binding pattern in rats and
mice exists and that activity and toxicity of rHuTNF would be
5–10 times less in rats as well. Therefore, 40 mg kg–1 rHuTNF in
the rat corresponds roughly with 4–8 mg kg–1 rHuTNF in the
human setting and thus indicates that the dose of TNF currently
used in the clinical setting (approximately 50 mg kg–1) may well be
reduced five- to tenfold while retaining synergy. Our experiments
show that further reduction leads to the complete loss of TNF
activity and thus to complete loss of synergy with melphalan.
These findings might be of clinical relevance in more than one
way. First, it suggests that the very high doses used presently in the
clinical setting may well be reduced while retaining efficacy, but
even more importantly this observation increases the chances that
TNF may become applicable in other settings such as isolated
hepatic perfusions (Fraker et al, 1994; Borel Rinkes et al, 1997;
Alexander et al, 1998; De Vries et al, 1998). These settings are
clearly less ideal, due to local toxicity, than the setting of the ‘inert’
limb perfusion.
In conclusion, our ILP rat model demonstrates strong syner-
gistic anti-tumour effects when TNF is combined with melphalan.
We identified as basic requirements for an effective ILP a duration
of 30 min and temperature of above 38°C, while hyperthermia
above 42°C resulted in unacceptable damage to the normal tissues.
Hypoxia was shown to enhance activity of melphalan and TNF
alone but did not further improve results of their combined use.
The minimally required dose of TNF to induce synergy with
melphalan was 10 mg (= 40 mg kg–1). These findings may serve
as important guidelines for further developments in ILP in the
clinical setting.
ACKNOWLEDGEMENTS
This work was financed in part by a grant from the Dutch Cancer
Society. The authors gratefully acknowledge Gert de Boeck for
performing melphalan concentration measurements and Ann
Seynhaeve for performing TNF–ELISA. Boehringer Ingelheim
GmbH is acknowledged for generously providing TNF.
REFERENCES
Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T and Rosenberg SA
(1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for
unresectable cancers confined to the liver. J Clin Oncol 12: 1479–1489
Asher AL, Mule JJ, Reichert CM, Shiloni E and Rosenberg SA (1987) Studies of the
antitumor efficacy of systemically administered recombinant tumor necrosis
factor against several murine tumors in vivo. J Immunol 138: 963–974
Benckhuijsen C, Kroon BBR, Van Geel AN and Wieberdink J (1988) Regional
perfusion treatment with melphalan for melanoma in a limb: an evaluation of
drug kinetics. Eur J Surg Oncol 14: 157–163
Borel Rinkes IHM, de Vries MR, Jonker AM, Swaak TJG, Hack CE, Nooijen
PTGA, Wiggers T and Eggermont AMM (1997) Isolated hepatic perfusion in
the pig with TNF-a with and without melphalan. Br J Cancer 75: 1447–1453
Broukaert P, Libert C, Everaerdt B and Fiers W (1992) Selective species specificity
of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res
11: 193–196
Clark J, Grabs AJ, Parson PG, Smithers BM, Addison RS and Roberts MS (1994)
Melphalan uptake, hyperthermic synergism and drug resistance in a human cell
culture model for the isolated limb perfusions of melanoma. Melanoma Res 4:
365–370
De Boeck G, van Cauwenberghe K, Eggermont AMM, van Oosterom AT and de
Bruijn EA (1997) Determination of melphalan and hydrolysis products in body
fluids by GC-MS. J High Res Chromat 20: 697–700
De Vries MR, Borel Rinkes IHM, van de Velde CJH, Wiggers T, Tollenaar RAEM,
Kuppen PJK, Vahnmeijer A and Eggermont (1998) Isolated hepatic perfusion
with tumor necrosis factor-a (TNFa) and melphalan. Rec Results Cancer Res
147: 107–119
Eggermont AMM (1996) Treatment of melanoma in-transit metastases confined to
the limb. Cancer Surv 26: 335–349
Eggermont AMM, Schraffordt Koops H, Liénard D, Kroon BBR, van Geel AN,
Hoekstra HJ and Lejeune FJ (1996a) Isolated limb perfusion with high-dose
TNF limb perfusion in a rat model 165
British Journal of Cancer (1999) 80(1/2), 161–166 © Cancer Research Campaign 1999tumor necrosis factor-a in combination with interferon-g and melphalan for
non-resectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol
14: 2653–2665
Eggermont AMM, Schraffordt Koops H, Klausner J, Kroon BBR, Schlag PM,
Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C,
Ben-Ari G, Pector JC and Lejeune FJ (1996b) Isolated limb perfusion with
tumor necrosis factor and melphalan for limb salvage in 186 patients with
locally advanced soft tissue extremity sarcomas: the cumulative multicenter
European experience. Ann Surg 224: 756–765
Engelberts I, Moller A, Schoen GJ, van der Linden CJ and Buurman WA (1991)
Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine
Cytokine Res 10: 69–76
Fajardo LF, Kwan HH, Kowalski J, Prionas SD and Allison AC (1992) Dual role of
tumor necrosis factor-a in angiogenesis. Am J Pathol 140: 539–544
Fraker DL, Alexander HR and Thom AK (1994) Use of tumor necrosis factor in
isolated hepatic perfusion. Circ Shock 44: 45–50
Fraker DL, Alexander HR, Andrich M and Rosenburg SA (1996) Treatment of
patients with melanoma of the extremity using hyperthermic isolated limb
perfusion with melphalan, tumor necrosis factor, and interferon gamma: results
of a tumor necrosis factor dose-escalation study. J Clin Oncol 14: 479–489
Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T and Thomas JM (1993) Low-
dose tumour necrosis factor a and melphalan in hyperthermic isolated limb
perfusion. Br J Surg 80: 995–997
Klaase JM, Kroon BBR, Benckhuijsen C, van Geel AN, Albus-Lutter CE and
Wieberdink J (1989). Results of regional isolation perfusion with cytostatics in
patients with soft tissue tumors of the extremities. Cancer 64: 616–621
Klostergaard J, Leroux E, Siddik ZH, Khodadadian M and Tomasovic SP (1992)
Enhanced sensitivity of human colon tumor cell lines in vitro in response to
thermochemoimmunotherapy. Cancer Res 52: 5271–5277
Kramer SM and Carver ME (1986) Serum-free in vitro bioassay for the detection of
tumor necrosis factor. J Immunol Methods 93: 201–206
Krementz ET, Carter RD, Sutherland CM and Hutton I (1977) Chemotherapy of
sarcomas of the limbs by regional perfusion. Ann Surg 185: 555–564
Kroon BBR, Klaase JM, van Geel AN and Eggermont AMM (1992) Application of
hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg
Cancer Treat 4: 223–226
Liénard D, Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ (1992) High-dose
recombinant tumor necrosis factor alpha in combination with interferon gamma
and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
J Clin Oncol 10: 52–60
Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL and
Eggermont AMM (1996) Synergistic antitumour effect of recombinant human
tumour necrosis factor a with melphalan in isolated limb perfusion in the rat.
Br J Surg 83: 551–555
Niitsu Y, Watanabe, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M and
Urushizaki I (1988) Synergistic effects of recombinant human tumor necrosis
factor and hyperthermia on in vitro cytotoxicity and artificial metastasis.
Cancer Res 48: 654–657
Nooijen PTGA, Manusama ER, Eggermont AMM, Schalkwijk L, Stavast J, Marquet
RL, de Waal RMW and Ruiter DJ (1996a) Synergistic anti-tumour effects of
TNF-a and melphalan in an isolated limb perfusion model of rat sarcoma: a
histopathologic, immunohistochemical and electron microscopic study. Br J
Cancer 74: 1908–1915
Nooijen PTGA, Eggermont AMM, Verbeek MM, Schalkwijk L, Buurman WA, de
Waal RMW and Ruiter DJ (1996b) Transient induction of E-selectin expression
following TNFalpha-based isolated limb perfusion in melanoma and sarcoma
patients is not tumor specific. J Immunother Emphasis Tumor Immunol 19:
33–44
Omlor G, Gross G, Ecker KW, Burger I and Feifel G (1992) Optimization of isolated
hyperthermic limb perfusion. World J Surg 16: 1117–1119
Posner M, Liénard D, Lejeune FJ, Rosenfelder D and Kirkwood J (1994)
Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha
(TNF) alone for metastatic in-transit melanoma. Proc Annu Meet Am Soc Clin
Oncol 13: A1351
Renard N, Liénard D, Lespagnard L, Eggermont A, Heimann R and Lejeune F
(1994) Early endothelium activation and polymorphonuclear cell invasion
precede specific necrosis of human melanoma and sarcoma treated by
intravascular high-dose tumour necrosis factor alpha (rTNFa). Int J Cancer 57:
656–663
Renard N, Nooijen PTGA, Schalkwijk L, de Waal RMW, Eggermont AMM, Liénard
D, Kroon BBR, Lejeune FJ and Ruiter DJ (1995) VWF release and platelet
aggregation in human melanoma after perfusion with TNFa. J Pathol 176:
279–287
Robins HI, d’Oleire F, Kutz M, Bird A, Schmitt-Tiggelaar CL, Cohen JD and
Spriggs DR (1995) Cytotoxic interactions of tumor necrosis factor, melphalan
and 41.8°C hyperthermia. Cancer Lett 89: 55–62
Scheringa M, Keizer A, Jeekel J and Marquet RL (1989) Anti-tumor effect of
recombinant TNF-alpha (rMuTNFa) given by continuous i.v. infusion as
compared to repeated i.v. injections in a rat metastasis model. Int J Cancer 43:
905–909
Scott RN, Kerr DJ, Blackie R, Hughes J, Burnside G, Mackie RM, Byrne DS and
McKay AJ (1992) The pharmacokinetic advantages of isolated limb perfusions
with melphalan for malignant melanoma. Br J Cancer 66: 159–166
Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J and Chaplin DJ (1995) The
cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake.
Anticancer Res 15: 219–224
Thompson JF and Gianoutsos MP (1992) Isolated limb perfusion for melanoma:
effectiveness and toxicity of cisplatin compared with that of melphalan and
other drugs. World J Surg 16: 227–233
Thompson JF, Waugh RC, Saw RPM and Kam PCA (1994) Isolated limb infusion
with melphalan for recurrent limb melanoma: a simple alternative to isolated
limb perfusion. Reg Cancer Treat 7: 188–192
Vaupel P, Kallinowski F and Okunieff P (1989) Blood flow, oxygen and nutrient
supply, and metabolic micro environment of human tumors: a review. Cancer
Res 49: 6449–6465
Vrouenraets BC, Kroon BBR, Ogilvie AC, van Geel AN, Nieweg OE, Swaak AJG
and Eggermont AMM (1997) Absence of severe systemic toxicity after leakage
controlled isolated limb perfusion (ILP) with high-dose TNFa and melphalan.
Melanoma Res 7: s111
Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M and
Urushizaki I (1988a) Synergistic cytotoxic and antitumor effects of
recombinant human tumor necrosis factor and hyperthermia. Cancer Res 48:
650–653
Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M and
Urushizaki (1988b) Toxic effect of tumor necrosis factor on tumor vasculature
in mice. Cancer Res 48: 2179–2183
Wu ZY, Smithers BM, Parsons PG and Roberts MS (1997) The effects of perfusion
conditions on melphalan distribution in the isolated perfused rat hindlimb
bearing a human melanoma xenograft. Br J Cancer 75: 1160–1166
166 JHW de Wilt et al
British Journal of Cancer (1999) 80(1/2), 161–166 © Cancer Research Campaign 1999